Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Cresco Labs Announces Voting Results of Its Annual General and Special Meeting of Shareholders

In This Article:

CHICAGO, July 10, 2024--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company"), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced the results of its annual general and special meeting of shareholders (the "Meeting") held on July 10, 2024.

At the Meeting, the number of directors on the board of directors of the Company for the ensuing year was fixed at eight (8) by the shareholders and the following nominees for election as directors of the Company were elected by a majority of votes cast by the shareholders virtually present or represented by proxy at the Meeting:

  • Charles Bachtell

  • Tarik Brooks

  • Gerald F. Corcoran

  • Marc Lustig

  • Thomas J. Manning

  • Randy D. Podolsky

  • Michele Roberts

  • Robert M. Sampson

Further, Marcum LLP was reappointed as the Company’s auditor for the ensuing year.

At the Meeting, shareholders passed an ordinary resolution to approve the Amended and Restated Cresco Labs Inc. 2018 Long-Term Incentive Plan (the "Amended Plan"). The Amended Plan provides for an increase in the share pool by adding 20,000,000 subordinate voting shares available for issuance under the Amended Plan. The share pool will remain at this increased amount until 10% of the issued and outstanding as-converted subordinate voting shares equals or exceeds such amount, after which the share pool will again be determined on a 10% rolling basis. Cresco Labs remains committed to a 10% rolling plan in the long-term, and the additional 20,000,000 subordinate voting shares will act as a temporary bridge to allow the Company to properly incentivize its employees and directors until the first date that there is equivalent capacity under a 10% rolling plan.

Shareholders of Cresco Labs also voted to approve the option exchange program ("Option Exchange") at the Meeting. Under the Option Exchange, certain employees were given the opportunity to exchange on a value-neutral basis certain out-of-the-money stock options for a lesser number of new stock options (the "New Options") with an exercise price equal to the higher of the closing price of the Company’s subordinate voting shares on the grant date of the New Options (the "New Option Grant Date") or the trading day preceding the New Option Grant Date. In addition to the benefits for employees, the Option Exchange reduced the Company’s equity overhang (the potential dilution represented by outstanding equity awards) by approximately 1.7 million shares.